124 related articles for article (PubMed ID: 35594612)
1. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
Amant F; Nekljudova V; Maggen C; Seither F; Neven P; Cardonick EH; Schmatloch S; Van Calsteren K; Cordes T; de Haan J; Lok CAR; Flock F; Boere IA; Gziri MM; Solbach C; Lefrère H; Schneeweiss A; Witzel I; Seiler S; Loibl S
Eur J Cancer; 2022 Jul; 170():54-63. PubMed ID: 35594612
[TBL] [Abstract][Full Text] [Related]
2. Survival in pregnancy-associated breast cancer patients compared to non-pregnant controls.
Martín Cameán M; Jaunarena I; Sánchez-Méndez JI; Martín C; Boria F; Martín E; Spagnolo E; Zapardiel I; Hernández Gutiérrez A
Reprod Biol Endocrinol; 2024 Mar; 22(1):34. PubMed ID: 38532462
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study.
Amant F; von Minckwitz G; Han SN; Bontenbal M; Ring AE; Giermek J; Wildiers H; Fehm T; Linn SC; Schlehe B; Neven P; Westenend PJ; Müller V; Van Calsteren K; Rack B; Nekljudova V; Harbeck N; Untch M; Witteveen PO; Schwedler K; Thomssen C; Van Calster B; Loibl S
J Clin Oncol; 2013 Jul; 31(20):2532-9. PubMed ID: 23610117
[TBL] [Abstract][Full Text] [Related]
4. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
6. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer.
Litton JK; Warneke CL; Hahn KM; Palla SL; Kuerer HM; Perkins GH; Mittendorf EA; Barnett C; Gonzalez-Angulo AM; Hortobágyi GN; Theriault RL
Oncologist; 2013; 18(4):369-76. PubMed ID: 23576478
[TBL] [Abstract][Full Text] [Related]
7. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial.
Bedognetti D; Sertoli MR; Pronzato P; Del Mastro L; Venturini M; Taveggia P; Zanardi E; Siffredi G; Pastorino S; Queirolo P; Gardin G; Wang E; Monzeglio C; Boccardo F; Bruzzi P
J Natl Cancer Inst; 2011 Oct; 103(20):1529-39. PubMed ID: 21921285
[TBL] [Abstract][Full Text] [Related]
8. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Results and Predictors of Survival After Conservative Breast Surgery for Breast Cancer During Pregnancy.
Feng C; Yu D; Qian J
Med Sci Monit; 2019 Nov; 25():8587-8594. PubMed ID: 31725704
[TBL] [Abstract][Full Text] [Related]
10. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis.
Crozier JA; Pezzi TA; Hodge C; Janeva S; Lesnikoski BA; Samiian L; Devereaux A; Hammond W; Audisio RA; Pezzi CM
Lancet Oncol; 2020 Dec; 21(12):1611-1619. PubMed ID: 33271091
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
12. Outcomes in patients with small node-negative invasive breast cancer.
Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
[TBL] [Abstract][Full Text] [Related]
13. Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study.
Maggen C; Dierickx D; Lugtenburg P; Laenen A; Cardonick E; Shmakov RG; Bellido M; Cabrera-Garcia A; Gziri MM; Halaska MJ; Ottevanger PB; Van Calsteren K; O'Laughlin A; Polushkina E; Van Dam L; Avivi I; Vandenberghe P; Woei-A-Jin FJSH; Amant F;
Lancet Haematol; 2019 Nov; 6(11):e551-e561. PubMed ID: 31564649
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of locally advanced breast cancer patients with ≥ 10 positive axillary lymph nodes.
Koca E; Kuzan TY; Dizdar O; Babacan T; Sahin I; Ararat E; Altundag K
Med Oncol; 2013; 30(3):615. PubMed ID: 23729267
[TBL] [Abstract][Full Text] [Related]
16. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer.
Gagliato Dde M; Gonzalez-Angulo AM; Lei X; Theriault RL; Giordano SH; Valero V; Hortobagyi GN; Chavez-Macgregor M
J Clin Oncol; 2014 Mar; 32(8):735-44. PubMed ID: 24470007
[TBL] [Abstract][Full Text] [Related]
18. Outcome of 561 non-metastatic triple negative breast cancer patients: multi-center experience from Turkey.
Budakoglu B; Altundag K; Aksoy S; Kaplan MA; Ozdemir NY; Berk V; Ozkan M; Algin E; Kandemir N; Dogu GG; Harputluoglu H; Arslan UY; Coskun U; Isikdogan A; Oksuzoglu B
J BUON; 2014; 19(4):872-8. PubMed ID: 25536589
[TBL] [Abstract][Full Text] [Related]
19. Association of Tumor-Associated Collagen Signature With Prognosis and Adjuvant Chemotherapy Benefits in Patients With Gastric Cancer.
Chen D; Chen H; Chi L; Fu M; Wang G; Wu Z; Xu S; Sun C; Xu X; Lin L; Cheng J; Jiang W; Dong X; Lu J; Zheng J; Chen G; Li G; Zhuo S; Yan J
JAMA Netw Open; 2021 Nov; 4(11):e2136388. PubMed ID: 34846524
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of triple negative phenotype in conservatively treated breast cancer.
Barbieri V; Sanpaolo P; Genovesi D
Breast J; 2011; 17(4):377-82. PubMed ID: 21615820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
